Literature DB >> 1805156

Surfactant substitution in ventilated very low birth weight infants: factors related to response types.

H Segerer1, P Stevens, B Schadow, R Maier, E Kattner, H Schwarz, T Curstedt, B Robertson, M Obladen.   

Abstract

We investigated factors than may influence the response to surfactant substitution. Thirty-five very low birth weight infants with respiratory distress syndrome were treated with Curosurf at 3-12 h of age. From the changes in oxygenation, the therapeutic response was categorized as rapid and sustained, rapid with relapse, or poor. Phospholipids and surfactant protein A were quantified in gastric aspirate samples obtained immediately after birth. They showed that 16 infants had accelerated lung maturity, despite clinical and radiologic signs of respiratory distress syndrome. Ten of them had suffered from birth asphyxia or connatal infection. Nevertheless, 12 of these 16 infants responded rapidly to surfactant substitution. Poor response was seen in four infants with connatal infection. Of 19 infants with immature lung profile, 18 showed a rapid initial response to surfactant substitution. Dynamic compliance of the respiratory system or arterial blood pressure before substitution, the ultrastructure of the surfactant preparation, or persistence of the ductus arteriosus did not influence the response type, but fraction of inspired oxygen was higher before surfactant substitution in infants with poor response. Prognosis was related to short-term response: Of 17 infants who showed a rapid and sustained response, none died, whereas eight of 18 infants with relapse after rapid initial response or poor response died (p less than 0.05). We conclude that surfactant substitution may be beneficial not only in babies with primary surfactant deficiency but also in other pulmonary disorders that are common in very low birth weight infants. The type of response may be of prognostic value.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1805156     DOI: 10.1203/00006450-199112000-00022

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  10 in total

1.  A risk-benefit assessment of natural and synthetic exogenous surfactants in the management of neonatal respiratory distress syndrome.

Authors:  H Walti; M Monset-Couchard
Journal:  Drug Saf       Date:  1998-05       Impact factor: 5.606

Review 2.  Porcine-derived lung surfactant. A review of the therapeutic efficacy and clinical tolerability of a natural surfactant preparation (Curosurf) in neonatal respiratory distress syndrome.

Authors:  L R Wiseman; H M Bryson
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

Review 3.  Liquid ventilation in the preterm neonate.

Authors:  C W Yoxall; N V Subhedar; N J Shaw
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

4.  Prognostic value of the immediate response to surfactant.

Authors:  J Kuint; B Reichman; L Neumann; E S Shinwell
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1994-11       Impact factor: 5.747

Review 5.  The fate of exogenous surfactant in neonates with respiratory distress syndrome.

Authors:  M Hallman; T A Merritt; K Bry
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

6.  Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study.

Authors:  S S Sehgal; C K Ewing; T Richards; H W Taeusch
Journal:  J Natl Med Assoc       Date:  1994-01       Impact factor: 1.798

7.  Surfactant protein A in the course of respiratory distress syndrome.

Authors:  P A Stevens; B Schadow; S Bartholain; H Segerer; M Obladen
Journal:  Eur J Pediatr       Date:  1992-08       Impact factor: 3.183

8.  Effect of surfactant and partial liquid ventilation treatment on gas exchange and lung mechanics in immature lambs: influence of gestational age.

Authors:  Carmen Rey-Santano; Victoria Mielgo; Elena Gastiasoro; Adolfo Valls-i-Soler; Xabier Murgia
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

9.  Goat lung surfactant for treatment of respiratory distress syndrome among preterm neonates: a multi-site randomized non-inferiority trial.

Authors:  Kajal Jain; Sushma Nangia; Vishnu Bhat Ballambattu; Venkataseshan Sundaram; M Jeeva Sankar; Siddharth Ramji; Sreenivas Vishnubhatla; Anu Thukral; Yogendra Kumar Gupta; Nishad Plakkal; Mangalabharathi Sundaram; Mamta Jajoo; Praveen Kumar; Kumutha Jayaraman; Ashish Jain; Arvind Saili; Anitha Murugesan; Deepak Chawla; Srinivas Murki; Ruchi Nanavati; Suman Rao; Umesh Vaidya; Ashish Mehta; Kamal Arora; Jayashree Mondkar; Sugandha Arya; Monika Bahl; Alpana Utture; Swati Manerkar; Swarna Rekha Bhat; Tushar Parikh; Manish Kumar; Anurag Bajpai; Sindhu Sivanandan; Pawandeep Kaur Dhawan; Gayatri Vishwakarma; Sudhakar Bangera; Sumit Kumar; Shridhar Gopalakrishnan; Atul Jindal; Chandra Kumar Natarajan; Anumeet Saini; Sukanya Karunanidhi; Meenakshi Malik; Parul Narang; Gurkirat Kaur; Chander Prakash Yadav; Ashok Deorari; Vinod K Paul; Ramesh Agarwal
Journal:  J Perinatol       Date:  2019-09       Impact factor: 2.521

10.  The effects of surfactant on oxygenation in term infants with respiratory failure.

Authors:  Serdar Beken; Canan Turkyılmaz; Esin Koc; Ibrahim M Hirfanoglu; Nilgun Altuntas
Journal:  Iran J Pediatr       Date:  2013-08       Impact factor: 0.364

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.